Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

31 results about "Cause of death" patented technology

In law, medicine, and statistics, cause of death is an official determination of conditions resulting in a human's death, which may be recorded on a death certificate. A cause of death is determined by a medical examiner. The cause of death is a specific disease or injury, in contrast to the manner of death which is a small number of categories like "natural", "accident", and "homicide", which have different legal implications.

Recombinant viral and non-viral vectors containing the human urokinase plasminogen activator gene and its utilization in the treatment of various types of hepatic, pulmonary, pancreatic and cardiac fibrosis and hypertrophic scars

Hepatic cirrhosis is considered a severe health problem in Mexico, since it is the third mortality cause in working-age people and there is no 100% effective treatment. Cirrhosis is characterized by an exacerbated increase of collagen in liver parenchyma, replacing the hepatocytes and thus provoking liver failure. This is one of the reasons why we have used a gene therapy through specific delivery to cirrhotic livers of the gene of human urokinase plasminogen activator (huPA), which activates mechanisms that induce the degradation of excess cellular matrix and stimulate hepatocyte proliferation, obtaining thus a fast re-establishment of the liver function. In the instant invention, the modified human uPA gene was inserted in the adenoviral vector (pAd-DeltahuPA), because it is not secreted and does not provoke hypercoagulation or spontaneous internal bleedings. Moreover, data from the bio-distribution essay with an adenoviral vector with reporter gene beta-gal have shown liver specificity as the target organ of the vector. Using ELISA, huPa protein was detected in liver homogenates (4500 pg/ml) in animals treated with pAd-DeltahuPA and was also intracellularly detected through immunochemistry in liver cuts (80% positive cells). huPa induced a dramatic fibrosis reduction (85%) on day 10 of vector administration, compared to control cirrhotic rats and 55% hepatocyte proliferation increase. Liver function tests (ALT, AST, alkaline phosphatase and bilirubin) dropped to nearly normal levels and hepatocyte proliferation was observed. Because of the two beneficial event cascades, gene therapy with modified huPA can be developed as a definite potential treatment for patients with liver cirrhosis.
Owner:TGT LAB DE C V

Liver cancer metastasis therapeutic device

The invention discloses a liver cancer metastasis therapeutic device, which is composed of a base plate, a prone support, a belly medicine massager, a chain wheel, a rotating wheel and a handheld massager, and used for recovering functions of a whole body. As shown in Schematic Diagram of Liver Cancer Metastasis Generation and Development Principle, Schematic Diagram of Liver Cancer Metastasis Therapeutic Principle and Technology, and Schematic Diagram of Death Causes and Death Process Change Rules of Patients with Liver Cancer Metastasis in a specification, in the focus generation period of cancerometastasis, cancer cells are killed mainly for eliminating metastasis focuses, attenuating symptom and delaying development of the focuses; in the death period of cancerometastasis, the functions of the whole body are recovered mainly for controlling development trend of the lesion and preventing death; functional lesion of the whole human body is the main factor for death, and systematic cancerometastasis focuses are secondary factors for death. The liver cancer metastasis therapeutic device is focused on recovering the functions of the whole human body with supplement of performing surgery and chemoradiotherapy for killing cancer cells to perform therapy aiming at causes of death, and thereby the target of significantly reducing a death rate of patients with metastasis of liver cancers and digestive organ cancers is achieved.
Owner:李复生
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products